A New Era in Biopharmaceutical Quality Assurance

The global biopharmaceutical industry is experiencing a shift in impurity control standards, driven by technological advancements and regulatory updates. Danish contract laboratory Alphalyse A/S is at the forefront of this transformation, offering a mass spectrometry (MS)-based approach that could redefine how biologics are assessed for quality and safety.

Since 2007, Alphalyse has been refining an MS-based impurity analysis method that drastically reduces the time required for pharmaceutical companies to identify and address contaminants in biological drugs. This innovation is especially critical as the industry grapples with increasingly stringent regulatory demands and the need for cleaner, more effective biopharmaceutical products.

The Impact of Mass Spectrometry on Biopharmaceuticals

Traditional impurity analysis methods, such as Enzyme-Linked Immunosorbent Assay (ELISA), can take over a year to adapt to new drugs. Alphalyse’s MS-based approach, by contrast, can be integrated into new biopharmaceutical projects within a few weeks. The efficiency gains from this method offer significant advantages, not only in time savings but also in ensuring a purer end product.

The significance of this breakthrough was underscored on December 1st, when the US Pharmacopeia expanded its guidelines to include a new method chapter detailing the best practices for MS analysis in biologics quality control. This move highlights the growing acceptance of MS as an industry standard, reinforcing Alphalyse’s role as a pioneer in this space.

“We have been collecting data for eight years, and it is now possible to systematically compare pharmaceuticals in our database with high precision. It’s crucial for quality assurance and efficiency that we can help the client with quality control of their products based on such an extensive databank. It’s likely to transform the way the biopharmaceutical industry looks at impurities,” says Thomas Kofoed, co-founder and CEO of Alphalyse.

A Breakthrough in Impurity Analysis

Alphalyse’s innovation lies not just in its analytical tools but also in the comprehensive database it has compiled over the years. This extensive collection of MS data allows pharmaceutical companies to compare their products against a wide range of biologics, providing insights into potential impurities and regulatory risks.

“The industry has lacked access to a database like ours. We can now advise clients if and how often we have identified specific protein impurities and give them unprecedented insight into their product. This database is a breakthrough in impurity analysis,” Kofoed adds.

As regulatory bodies increase their focus on drug purity, having access to a repository of impurity data provides pharmaceutical companies with a crucial advantage. The ability to assess and mitigate contamination risks early in the development process could lead to more successful drug approvals and fewer clinical trial failures.

Regulatory Implications and Industry Adoption

US Pharmacopeia guidelines play a pivotal role in establishing industry-wide best practices, and experts predict that MS-based analysis will soon become a standard regulatory requirement. Dr. Lars Skriver, senior science officer at Savara Pharmaceuticals, sees this shift as inevitable.

“Protein impurities are a great source of concern, and regulatory authorities are focusing more on drug impurities than ever before. Alphalyse aims to be a thought leader in establishing new quality standards for pharmaceutical impurity control,” says Skriver.

He further explains how Alphalyse’s database provides a unique advantage: “Many companies can perform protein analysis, but Alphalyse’s database provides an overview of which specific polluting agents you can anticipate in the production process of various biologics, and this is a major benefit. In addition, the traditional (ELISA) method can take more than a year to adapt to a new drug. Alphalyse’s cutting-edge analysis tools and database reduce the analysis development process by several months.”

A Global Head Start in Quality Control

With its proprietary MS techniques and database, Alphalyse is well-positioned to expand its reach, particularly in the United States, where the Food and Drug Administration (FDA) frequently aligns with US Pharmacopeia recommendations. The company aims to strengthen collaborations with pharmaceutical firms looking to streamline impurity analysis and regulatory compliance.

“Alphalyse has developed one of the methods recommended in the US Pharmacopeia, and we are the most experienced laboratory in the world for MS analysis of biologics impurities. We offer a service that helps pharmaceutical companies optimize the development and production of biologics, ensuring that new products are cleaner, cheaper to produce, have longer shelf life, and cause fewer side effects for patients,” says Kofoed.

Looking ahead, Alphalyse believes that the integration of MS analysis in pharmaceutical development will lead to significant industry-wide benefits. “We hope the industry will seriously consider how powerful MS analysis is for the quality assurance of biologics – and look into the ability to collect data actively for risk evaluation and production standardization. It should lead to fewer drugs failing in clinical trials and more products reaching the market. We’ll probably see a growing number of innovative therapies for treating diseases such as multi-resistant bacteria, cancer, and Alzheimer’s – and in the case of a new pandemic, it will be possible to develop new vaccines much faster than ever before.”

The Future of Biopharmaceutical Impurity Control

With regulatory support and industry adoption on the rise, MS-based impurity analysis is set to become a fundamental component of biopharmaceutical quality control. Alphalyse’s pioneering work not only accelerates drug development timelines but also enhances patient safety by reducing the risk of contamination.

As pharmaceutical companies strive to meet evolving regulatory expectations, access to high-precision analytical tools and comprehensive impurity data will become increasingly essential. With its extensive database and expertise in MS-based protein analysis, Alphalyse is poised to play a crucial role in shaping the future of biopharmaceutical quality assurance.

By embracing these advances, the industry stands to benefit from improved efficiency, reduced costs, and ultimately, the ability to bring safer, more effective drugs to market at an unprecedented pace.